Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Lagerbericht

Marktkapitalisierung: US$15.7m

Citius Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Gewinne von Citius Pharmaceuticals sind mit einer durchschnittlichen Jahresrate von -12.1% zurückgegangen, während die Gewinne der Branche Pharmaceuticals um 9.7% pro Jahr wuchsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Jahresrate von 104.6%.

Wichtige Informationen

-12.10%

Wachstumsrate der Gewinne

10.30%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie5.95%
Wachstumsrate der Einnahmen104.56%
Eigenkapitalrendite-80.27%
Netto-Marge-823.34%
Letzte Ertragsaktualisierung31 Mar 2026

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

Analyseartikel • Apr 06

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Dec 08

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analyseartikel • Aug 01

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Apr 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analyseartikel • Dec 25

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 28

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals (NASDAQ:CTXR) on Wednesday said it had submitted a biologics license application (BLA) to the U.S. FDA for its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. According to CTXR, I/ONTAK (denileukin diftitox) is a purified and more bioactive formulation of previously FDA-approved therapy ONTAK. The BLA submission was supported by results from a phase 3 study. The submission comes after CTXR held a pre-BLA meeting with the FDA in July. The company in May had said that it planned to form a new company focused on developing and commercializing I/ONTAK, with an IPO planned for H2 2022. "The BLA filing for denileukin diftitox marks the first of our pipeline candidates to be submitted for FDA approval," CTXR CEO Leonard Mazur said in Wednesday's statement. Citius Pharmaceuticals (CTXR) stock -0.9% to $1.17 in premarket trading.
Seeking Alpha • Aug 11

Citius Pharmaceuticals GAAP EPS of -$0.06

Citius Pharmaceuticals press release (NASDAQ:CTXR): Q3 GAAP EPS of -$0.06. The company has reported $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023
Analyseartikel • Aug 05

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 12

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals (NASDAQ:CTXR) on Tuesday said it had held a pre-biologics license application (BLA) meeting with the U.S. FDA to discuss its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. "Based on the FDA's pre-BLA meeting comments, we intend to move forward with our planned BLA submission for I/ONTAK in the second half of 2022," said CTXR CEO Leonard Mazur. The purpose of the pre-BLA meeting was to discuss the content and acceptability of the company's anticipated BLA for I/ONTAK. Citius (CTXR) in May had said that it planned to form a new company focused on developing and commercializing I/ONTAK, with an IPO planned for H2 2022. CTXR stock +1.3% to $0.92 in premarket trading.
Seeking Alpha • Jul 05

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated. Calculations show that Citius' current cash reserves of $55.8 million will only last the company until December 2022, just when it is expected to complete patient enrolment. There is a buy-out possibility after the company announced its intention to spin-off I/Ontak less than a year after license acquisition. Late-stage biopharmaceuticals company Citius Pharmaceuticals, Inc. (CTXR) informed investors that it had selected Biorasi to help it expand its Phase 3 Mino-Lok trial to clinical sites outside the U.S. Well, that formed one of the main highlights of Q2 2022, with investors yet to hear any news about patient enrolment almost 2 months after Biorasi's appointment. Still, there is a lot of excitement among investors with Citius expected to file its biologics license application ((BLA)) for I/ONTAK with the U.S. Food and Drug Administration ((FDA)) later in the second half of 2022. Thesis In this article, I will explain why I am raising my rating of CTXR to hold from sell. The plan to spin off I/Ontak as a standalone company appears to be a strategic move to spearhead growth and attract new investors to the company. As a pure-play oncology-focused biopharmaceutical project, the new company may leverage past mistakes that have delayed the release of topline data for Mino-Lok. Further, new acquisitions are in the offing, especially since the company's finances are inadequate to sustain the company for the next 12 months. Earlier Assessment In my previous article on CTXR, I expressed my concerns over the company's rush to buy E7777 where it burnt a significant amount of cash. Citius is yet to recover, and it is now on the verge of forming a new company to develop and commercialize I/Ontak. This decision comes as no surprise since it had already completed the Phase 3 trial in December 2021. Additionally, the pipeline development for the two main drug candidates: Mino-Lok and E7777 were on different trajectories. Apart from I/Ontak and Mino-Lok, Citius also has in its pipeline Halo-lido, Mino-Wrap, and a Stem cell platform. At the moment, the market is in a bear mode with investors eagerly waiting for some good news within the pipeline development to squeeze the shorts. For Citius, it has been a long time coming. In July 2021, CTXR announced a positive recommendation by the Independent Data Monitoring Committee ((IDMC)) to proceed with the planned Mino-Lok Phase 3 Trial. One year later, the company is yet to release test results. However, with the entry of Biorasi, we expect the company to fast-track patient enrolment. Overview of Patient enrolment and Phase 3 Trial Dynamics The total number of patients planned for Mino-Lok's phase 3 trial is 144, distributed as 1:1 to the standard of care ((SOC)) which is antibiotics. The objective of this trial (as noted in our earlier report) is to evaluate Mino-Lok's efficacy in salvaging colonized central venous catheters in patients with catheter-related or central line-associated bloodstream infection (CRBSI/ CLABSI). This evaluation is compared to the SOC of using antibiotics. In this trial, the protocol will be focused on reaching 92 catheter failure events that also correspond to the 144 patients. Albeit, the company is yet to disclose how many patients it has tested so far and how many events are in the balance. The primary endpoint is the time until catheter failure occurs, expressed in days from randomization into one of the two study arms. Simply put, this means that a patient with a catheter develops a bacterial infection, is subsequently assigned to one of the two study arms, and from then on, the time in days until the catheter needs to be replaced is noted. In the description of the study, this is given as a time frame of 6 weeks. To be able to show the statistical superiority of Mino-Lok over SOC, the time to catheter failure was defined as at least 38 days for Mino-Lok versus 21 days for SOC. The trial started in February 2018 and reached 40% enrollment in September 2019. The next 50% were reached in February 2020 and later 80% were reached in June 2021. This fits pretty nicely to a rate of 2% enrollment per month. It is interesting to note here that the normally increasing speed of enrollment throughout a study due to clinics being added and the slowdown of the study due to the COVID-19 pandemic have balanced each other out. However, there was a fundamental change by Q4 2021. Despite the increasing number of patients during the Covid19 pandemic, the company still expected a prolonged trial that would affect enrolment. This problem necessitated the recruitment of Biorasi. Citius CEO, Myron Holubiak was optimistic about the company's accomplishments in 2022, despite the apparent delays. He stated, As we move into 2022, we anticipate multiple positive milestones. These include accelerated enrollment and completion of the Mino-Lok trial during the year, topline results in the first half of 2022 for the recently completed I/ONTAK (E7777) Pivotal Phase 3 trial followed by a BLA submission in the second half of the year." Before this date, CTXR always said that topline data for Mino-Lok will be published in 2022, suddenly it changed and only completion of the trial (meaning full enrollment) is planned. Right now, there is no further update on the actual state of the enrollment. In February, CTXR again stated that trial completion will be reached in 2022 leaving open the final date for topline data. Enrollment must be higher than 80% but seems to be very slow. CTXR plans to reach full enrollment by the end of 2022. Now, with the help of Biorasi, this could be fastened up. But still, CTXR plans year-end 2022 for full enrollment and as long as we have no further update, we have to calculate with this. Questions are: What happened to the speed of the enrollment in H2 2021? Why was Biorasi asked for help so late? One could have added clinics in other countries also right from the beginning to keep the Phase 3 trial short. I have no idea why they waited so long for this step. Of special note is that the FDA does not require a certain number of patients but wants to see two adequate and well-designed clinical trials. With regards to Mino-Lok, the completed Phase 2 and the ongoing Phase 3 trials will be sufficient. The number of patients per trial strongly depends on the indication, the trial design and the statistical calculations planned and thus are different for every trial. The planned 144 patients in Phase 3 is enough for FDA approval if the results are good, and statistically significant to prove that Mino-Lok is safe. So what is remaining as far as Mino-Lok is concerned? In presenting its phase 3 topline data, Citius will first hold a Pre-NDA (New Drug Application) meeting with the FDA to talk about the NDA filing and if data are enough. It's the first check by FDA if there are enough data. Sometimes FDA demands additional trials, which can be small or even a full Phase 3 trial. Also, check with FDA if any designations will shorten the review process of the FDA from 10 to 6 months. Mino-Lok already was granted fast-track designation by the FDA meaning that their review process will be only 6 months. Writing the NDA application is a time-based process. It must contain all clinical, and pre-clinical data and manufacturing details. It is expected that it will take at least 6 months from filing to submission of data to the FDA (after the release of topline data). After filing the NDA, the FDA takes 2 months to approve or reject the data. After approval, the FDA needs another 6 months (with fast-track designation, otherwise it takes 10 months) to check the NDA and decide about the approval of Mino-Lok. Thus, in general, CTXR has to prepare everything about Mino-Lok including all results and data but also how it is manufactured and the corresponding documents that prove good manufacturing practice and quality control mechanisms, etc. This means that from topline data onward I believe CTXR will need at least 6 months until NDA submission, followed by a total of 8 months (2 months needed by the FDA to accept the filing and 6 months to review the NDA) until the FDA will finally decide if Mino-Lok is approved. This means with topline data in H1 2023, approval could be in mid-2024. Selling Halo-Lido? Investors are looking forward to CTXR's selling of Halo-Lido, especially after the Phase 2B trial. Whether it will be a possibility or not remains a subject under discussion. Still, the company desperately needs financial backup. Before we address the financial standpoint, we need to underscore the fact that the FDA is yet to approve a prescription drug for the treatment of hemorrhoids. Once approved, Halo-Lido could become the first drug to treat hemorrhoids in the US. Citius Chairman, Leonard Mazur confirmed that the company had received several interested buyers back in 2021. We can speculate that one of the buyers may be interested in buying out Citius but may not be interested in I/Ontak or E7777- the reason for the spin-off.
Seeking Alpha • Apr 13

Critical Care Biopharma - Citius Pharmaceuticals

Citius Pharmaceuticals is a late-stage biopharma focused on critical care products. Preventing shareholder dilution. Resumption of clinical trials after COVID-19.
Seeking Alpha • Mar 28

Citius: 2022 Is A Year Of Catalysts

5 Active Programs With Near Term Catalysts. I/ONTEK Topline Data Release Expected As Early As April. Price Target of $10.
Analyseartikel • Dec 04

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 26

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Citius stock price reacted to no safety concerns identified by the DMC, to surge 102.86% (YoY) and +108.82% (YTD). Citius has prioritized E7777 threatening to derail the company's progression with Mino-Lok. Continual medical development may overthrow the use of CVCs due to the high mortality rate of 12%-25% associated with CLABSI. With a cash balance of $115.7 million, Citius will likely incur a loss in the E7777 transaction. It requires an upfront payment of $40 million and milestone payments of up to $110 million.
Analyseartikel • Aug 28

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Citius...

Aufschlüsselung der Einnahmen und Ausgaben

Wie Citius Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqCM:CTXR Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Mar 266-46546
31 Dec 254-36319
30 Sep 250-37299
30 Jun 250-413110
31 Mar 250-433112
31 Dec 240-413111
30 Sep 240-403012
30 Jun 240-402912
31 Mar 240-372613
31 Dec 230-392514
30 Sep 230-342215
30 Jun 230-311816
31 Mar 230-311717
31 Dec 220-281616
30 Sep 220-341618
30 Jun 220-311516
31 Mar 220-291513
31 Dec 210-261312
30 Sep 210-251112
30 Jun 210-241111
31 Mar 210-21912
31 Dec 200-21912
30 Sep 200-1899
30 Jun 200-1789
31 Mar 200-1789
31 Dec 190-1679
30 Sep 190-1679
30 Jun 190-1578
31 Mar 190-1276
31 Dec 180-1368
30 Sep 180-1377
30 Jun 180-1375
31 Mar 180-1385
31 Dec 170-1182
30 Sep 170-1073
30 Jun 170-1074
31 Mar 170-1165
31 Dec 160-954
30 Sep 160-853
30 Jun 160-732
31 Mar 160-422
31 Dec 150-312
30 Sep 150-312

Qualität der Erträge: CTXR ist derzeit unrentabel.

Wachsende Gewinnspanne: CTXR ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: CTXR ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 12.1% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von CTXR verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: CTXR ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Pharmaceuticals (-5%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: CTXR hat eine negative Eigenkapitalrendite (-80.27%), da es derzeit unrentabel ist.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/21 13:06
Aktienkurs zum Tagesende2026/05/21 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/09/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Citius Pharmaceuticals, Inc. wird von 4 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Jason KolbertD. Boral Capital LLC.
Swayampakula RamakanthH.C. Wainwright & Co.
Jason McCarthyMaxim Group